Summary
The DEA’s final order establishing 2025 Aggregate Production Quotas (APQs) for all Schedule I and II controlled substances, including stimulants used to treat ADHD. Published December 17, 2024 in the Federal Register. Received 1,882 public comments — a record response — concentrated on opioid adequacy and stimulant drug shortages. The document reveals the quota-setting mechanics, DEA’s responses to shortage complaints, and the institutional constraints on increasing supply.
Key Points
- Legal mechanism: Under the Controlled Substances Act (21 U.S.C. 826), the DEA Administrator must set Aggregate Production Quotas annually — hard caps on how much of each substance can be manufactured in the U.S. that year. No manufacturer can exceed their individual quota, which is derived from the APQ.
- ADHD stimulant response: DEA received comments “expressing general concerns regarding the ongoing drug shortages for stimulant medications used in the treatment of ADHD.” DEA’s response: it sets APQs based on “estimated legitimate medical needs” at the time; if prescribing rates are “significantly higher than estimates,” the Administrator “has the authority to increase the aggregate production quota at any time.”
- The gap: The admission that actual prescribing rates could be “significantly higher than 2025 estimates” — combined with the FDA-declared shortage that has persisted since October 2022 — demonstrates the quota system lags demand. DEA acknowledged this without committing to a fix.
- Opioid quota reductions: The document establishes 2025 opioids quotas at approximately the same level as 2024, with ~0.1% combined reduction for diversion adjustments. Critics say even holding steady perpetuates pharmacy-level shortages.
- GHB quota increase: GHB (sodium oxybate) APQ increased 70% to 49.7M grams to accommodate new FDA-approved generics entering the market. Shows DEA can move quickly when it chooses to.
- Transparency gap: Two commenters flagged a “lack of transparency” in the quota-setting process. DEA said it is “considering methods” to increase transparency — no commitment.
- New substance (DMT): DEA increased the DMT quota in response to manufacturer requests for FDA drug development research — indicating psychedelic drug development pipeline is advancing.
Newsletter Angles
- ADHD Medication Shortage: This is the primary government document at the center of the shortage. The DEA’s own response — “we can increase quotas if prescribing rates significantly exceed estimates” — reveals the mechanism and the accountability gap. If shortages are documented and persistent (since October 2022), why haven’t quotas been adjusted? The DEA didn’t answer that.
- The manufactured scarcity dynamic: DEA sets quotas based on past prescribing data, not current demand. As ADHD diagnoses increase (including adult diagnosis boom), the quotas chase rather than lead demand. This is a structural feedback loop, not an accident.
- GHB as contrast: DEA increased GHB supply by 70% in one cycle when pharmaceutical companies applied. The stimulant shortage has persisted for three years. The difference may be the nature of applicants (pharma companies vs. diffuse patient advocacy) and the political economy of ADHD medication.
Entities Mentioned
No named entities in this document. The DEA itself is the institutional actor.
Concepts Mentioned
- ADHD Medication Shortage — this is the primary regulatory document governing the shortage; the APQ mechanism is the chokepoint the DEA’s Manufactured Crisis article describes
Quotes
“If the actual prescribing rates of these substances are significantly higher than the 2025 estimates of medical needs, the Administrator has the authority to increase the aggregate production quota at any time.”
DEA on the shortage: “DEA is committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet the estimated legitimate medical, scientific, research, and industrial needs of the United States.”
Notes
The actual quota figures for each substance span multiple printed Federal Register pages (the clipping contains page breaks but not the numbers themselves). The key analytical value is the public comment response and DEA’s explanations for its quota-setting methodology.